Home > Healthcare > Pharmaceuticals > Finished Drug Form > infectious enteritis treatment market
Get a free sample of Infectious Enteritis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Infectious Enteritis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The infectious enteritis treatment industry hosts numerous companies competing for market share. Key players dominate with their comprehensive treatment offerings for gastrointestinal disorders such as IBS and enteritis. These companies compete through product innovation, regulatory approvals, and strategic partnerships to capture market share and address the diverse needs of patients and healthcare providers.
Some of the prominent players operating in the infectious enteritis treatment industry include:
Abbott Laboratories, Almirall SA, AstraZeneca PLC, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, GSK plc, Medimetriks Pharmaceuticals Inc., Merck KGaA, and Pfizer Inc. among others.
U.S. infectious enteritis treatment market size was 167.9 million in 2023 and will show significant growth over the analysis period, driven by favorable regulatory frameworks, coupled with the introduction of advanced products.
Infectious enteritis treatment industry from the antibiotics drug type segment will reach USD 388.5 million by end of 2032, owing to its ability to effectively target various enteric infections in adults.
The infectious enteritis treatment market size was valued at USD 434.8 million in 2023 and will grow at 6.3% CAGR from 2024 to 2032, propelled by the rising incidence of infectious diseases globally.